Irene M. C.
- Country
- Spain
- Department
- 3304: Oncologia
Research Overview
- Evaluation of RP3 Monotherapy and RP3 Plus Nivolumab in Patients with Advanced Solid Tumors
- A Phase I/II Study of KISIMA-02 Vaccine-Based Immunotherapy in KRAS G12D/G12V Mutated Pancreatic Ductal Adenocarcinoma Patients
- Dose-Escalation Study of [177Lu]Lu-DOTA-TATE with Standard Care in Newly Diagnosed Glioblastoma and as Monotherapy in Recurrent Glioblastoma.
Data & Insights
Has run more than one trial at 109 of 193 partner sites.
Specializations
Breast Cancer and Hormone-Receptor-Driven Disease
Irene Moreno Candilejo is actively involved in clinical research across advanced breast cancer, with strong emphasis on ER-positive, HER2-negative, HER2-positive, and triple-negative breast cancer. Her trial portfolio also includes early-stage and metastatic settings, as well as biomarker-defined populations such as ESR1-mutated and BRCA-altered disease.
- Hormone receptor-positive breast cancer
- HER2-directed therapy
- Early and metastatic breast cancer
- Biomarker-selected breast cancer
Her work spans endocrine-based treatment strategies, targeted combinations, and antibody-drug conjugate approaches in breast oncology.
Thoracic Oncology and Lung Cancer
Her research activity includes a broad range of non-small cell lung cancer and small cell lung cancer settings, covering locally advanced, metastatic, and treatment-resistant disease. She is also involved in studies focused on molecular subsets such as EGFR exon 20 insertion, ALK, RET, and ROS1 alterations.
- Non-small cell lung cancer
- Small cell lung cancer
- Oncogene-driven lung cancer
- Advanced thoracic malignancies
Her portfolio reflects interest in immunotherapy combinations, targeted agents, and treatment options for advanced lung malignancies.
Gastrointestinal Oncology and Hepatopancreatobiliary Cancers
Her clinical trial involvement extends across colorectal cancer, gastric cancer, gastroesophageal junction adenocarcinoma, pancreatic ductal adenocarcinoma, cholangiocarcinoma, and hepatocellular carcinoma. She also contributes to research in esophageal cancer and other advanced gastrointestinal malignancies.
- Colorectal cancer
- Gastric and gastroesophageal junction cancer
- Pancreatic cancer
- Biliary tract and liver cancer
Her studies include precision-medicine approaches and combination strategies for advanced digestive system tumors.
Gynecologic Oncology and Urologic Malignancies
Irene Moreno Candilejo is involved in trials for ovarian cancer, endometrial cancer, cervical cancer, uterine carcinoma, and fallopian tube and primary peritoneal cancers. Her research also includes urothelial carcinoma, bladder cancer, and renal cell carcinoma, with a focus on advanced and recurrent disease.
- Ovarian and endometrial cancer
- Cervical and uterine malignancies
- Urothelial carcinoma
- Renal cell carcinoma
Her portfolio includes targeted and immune-based strategies in genitourinary and gynecologic oncology.
Hematologic Malignancies and Selected Solid Tumor Innovation
Her research landscape also covers multiple myeloma, acute myeloid leukemia, myelodysplastic syndromes, and diverse B-cell lymphomas. In parallel, she participates in studies of melanoma, glioblastoma, and other advanced solid tumors, including biomarker-defined populations.
- Multiple myeloma
- Acute myeloid leukemia
- Lymphoma
- Melanoma and glioblastoma
Her trial involvement reflects engagement with immunotherapy, targeted therapy, and precision oncology across hematologic and solid tumor settings.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.